CAPTRUST Financial Advisors
NGM

CAPTRUST Financial Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

CAPTRUST Financial Advisors’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-62
Closed -$1K – 5201
2021
Q4 		$1K Sell
62
-149
-71% -$2.86K ﹤0.01% 4664
2021
Q3 		$4K Buy
211
+113
+115% +$2.49K ﹤0.01% 4066
2021
Q2 		$2K Buy
98
+2
+2% +$47 ﹤0.01% 4226
2021
Q1 		$3K Buy
+96
New +$2.69K ﹤0.01% 3959

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAPTRUST Financial Advisors's NGM Position: Q1 2022 in Review

CAPTRUST Financial Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2022, closing a stake of 62 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in NGM in Q1 2021 and held it in 4 quarters. The position peaked at $4K in Q3 2021. 114 funds tracked by Wall St. Rank hold NGM as of Q1 2022.

  • CAPTRUST Financial Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 62 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 4 quarters.
  • CAPTRUST Financial Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $4K in Q3 2021.
  • 114 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2022, filed 16 May 2022.